GenesisCare Newcastle
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Martin, Jarad M
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
SABRE, NCT04905069: Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy

Recruiting
N/A
500
Europe, US, RoW
SpaceOAR Vue System
Boston Scientific Corporation
Prostate Cancer
04/27
04/30
Lynch, Jayd
ProstACTSelect, NCT04786847: 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study

Completed
1
30
RoW
177Lu-DOTA-TLX591
Telix International Pty Ltd
Metastatic Prostate Cancer
09/23
09/23

Download Options